Tango Therapeutics Files 8-K on Shareholder Votes and Financials
Ticker: TNGX · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1819133
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
TL;DR
Tango Therapeutics filed an 8-K on June 5, 2024, covering shareholder votes and financials.
AI Summary
Tango Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders and financial statements. The company, formerly BCTG Acquisition Corp. until July 23, 2020, is incorporated in Delaware and based in Boston, MA.
Why It Matters
This filing provides updates on corporate actions and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating new material risks.
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Registrant
- BCTG Acquisition Corp. (company) — Former company name
- 20240606 (date) — Filing date
- June 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Boston, MA (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not elaborated upon in the provided text.
What is the significance of the 'Former Company' information?
The filing notes that Tango Therapeutics, Inc. was formerly known as BCTG Acquisition Corp. until July 23, 2020, indicating a name change or corporate restructuring.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 5, 2024.
What is the primary business of Tango Therapeutics, Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code provided, Tango Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry.
Where are Tango Therapeutics, Inc.'s principal executive offices located?
Tango Therapeutics, Inc.'s principal executive offices are located at 201 Brookline Ave., Suite 901, Boston, MA 02215.
Filing Stats: 1,047 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-06-06 16:06:00
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share TNGX The Nasdaq Global Ma
Filing Documents
- d768398d8k.htm (8-K) — 39KB
- d768398dex31.htm (EX-3.1) — 7KB
- 0001193125-24-156048.txt ( ) — 178KB
- tngx-20240605.xsd (EX-101.SCH) — 3KB
- tngx-20240605_lab.xml (EX-101.LAB) — 19KB
- tngx-20240605_pre.xml (EX-101.PRE) — 12KB
- d768398d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment of the Restated Certificate of Incorporation of Tango Therapeutics, Inc. 104 Cover Page Interactive Data File (Embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TANGO THERAPEUTICS, INC. Dated: June 6, 2024 By: /s/ Douglas Barry Name: Douglas Barry Title: General Counsel